Pharvaris N.V. announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil. Prof. Markus Magerl, M.D., presented an oral session titled ?Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase 2 Trial Results? on December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST).

RAPIDe-1, a pivotal Phase 2 trial of deucrictibant immediate-release capsule (PHVS416) in the on-demand treatment HAE attacks, showed that deucrictibant capsules rapidly reduced time to the onset of symptom relief and to the resolution of HAE attacks, substantially reduced use of rescue medication and was well-tolerated at all dose levels. Prof. Marcus Maurer, M.D., presented a poster titled ?Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant? on December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST).

Primary and post-hoc analyses of the RAPIDe-1 study were conducted to evaluate end of progression (EoP) and symptom relief in response to treatment of HAE attacks with PHVS416. In a post-hoc analysis of RAPIDe-1 data, EoP of angioedema manifestations, which represents the first event documenting treatment response and the first evidence of attacks evolving towards relief and resolution, was achieved at a median time of 25 or 26 minutes after treatment with deucrictibant capsules versus 20 hours for placebo. The onset of symptom relief was achieved at approximately two hours and clinically meaningful improvement within two hours after administration of deucrictibant.

Dr. Danny M. Cohn, M.D., presented a poster titled ?Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S? on December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST). This poster details findings from a study performed in the U.S. assessing the content validity and psychometric properties of the three-item Angioedema symptom Rating scale (AMRA-3), a numeric rating scale derived from the three-symptom composite visual analogue scale (VAS-3). Results suggest that the median time to symptom relief of an AMRA-3 =20% reduction from pre-treatment is comparable with achieving a Patients' Global Impression of Change (PGI-C) ?a little better?

on two consecutive timepoints.